In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter;Effets modulateurs de collyres anti-allergiques sur l'activation du complément induite in vitro par des polluants particulaires

Journal Francais d'Ophtalmologie

Volumn 26, Issue 4, 2003, Pages 328-336

  Blondin, C ^a,b,c   Cholley, B ^a   Haeffner Cavaillon, N ^a   Goldschmidt, P ^b  

^a HÔPITAL BROUSSAIS   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

Author keywords

Anti allergic eyedrops; Complement system; Inflammation; Pollution; Pseudoallergic conjunctivitis

Indexed keywords

ALLERGEN; ALMIDE; AZELASTINE; BENZALKONIUM CHLORIDE; COMPLEMENT; COMPLEMENT INHIBITOR; COSMETIC; DRUG PRESERVATIVE; EMEDASTINE; EYE DROPS; IODOXAMIC ACID; IODOXAMIDE; KETOTIFEN FUMARATE; LEVOCABASTINE; LEVOPHTA; N ACETYLASPARTYLGLUTAMIC ACID; NAABAK; NEDOCROMIL SODIUM; OLOPATADINE; POLLEN EXTRACT; UNCLASSIFIED DRUG; ZYMOSAN;

AIR POLLUTANT; AIR POLLUTION; ALLERGY; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT HEMOLYSIS TEST; COMPLEMENT INHIBITION; CONJUNCTIVITIS; DRUG EFFECT; DRUG FORMULATION; EYE BURNING; EYE INFLAMMATION; FOREIGN BODY; HOUSE DUST; HUMAN; INDOOR AIR POLLUTION; PARTICULATE MATTER; PHOTOPHOBIA; POLLEN; RISK FACTOR; SAND; SERUM; SYMPTOM;

AIR POLLUTANTS; ANTI-ALLERGIC AGENTS; BENZALKONIUM COMPOUNDS; BENZIMIDAZOLES; COMPLEMENT ACTIVATION; CONJUNCTIVITIS; COSMETICS; DIBENZOXEPINS; DIPEPTIDES; DRUG EVALUATION; DUST; HUMANS; KETOTIFEN; NEDOCROMIL; OPHTHALMIC SOLUTIONS; OXAMIC ACID; PHTHALAZINES; PIPERIDINES; POLLEN; SILICON DIOXIDE; ZYMOSAN;

EID: 0038296028     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Morgan BP. The complement system: an overview. Methods Mol Biol, 2000;150:1-13.
2. Mollnes TE, Song WC, Lambris JD. Complement in inflammatory tissue damage and disease. Trends Immunol, 2002;23:61-4.
3. Willcox MDP, Morris CA, Thakur A, Sack RA, Wickson J, Boey W. Complement and complement regulatory proteins in human tears. Invest Ophthalmol Vis Sci, 1997;38:1-8.
4. Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest Ophthalmol Vis Sci, 2000;41:3492-502.
5. Bardenstein DS, Cheyer CJ, Lee C, Cocuzzi E, Mizuno M, Okada N, Medof ME. Blockage of complement regulators in the conjunctiva and within the eye leads to massive inflammation and iritis. Immunology, 2001;104:423-30.
6. Cocuzzi E, Guidubaldi J, Bardenstein DS, Chen R, Jacobs MR, Medof EM. Release of complement regulatory proteins from ocular surface cells in infection. Curr Eye Res, 2000;21:856-66.
7. Cruz JC, Sohn JH, Suk HJ, Bora PS, Kaplan NS. Complement activation via the alternative pathway causes a rapid-onset anterior uveitis. ARVO meeting, Fort Lauderdale, May 5-10, 2002, Abstract 2280, Program Summary Book, p. 91.
8. Gerl VB, Bohl J, Pitz S, Stoffelns B, Pfeiffer N, Bhakdi S. Extensive deposits of complement C3d and C5b-9 in the choriocapillaries of eyes of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci, 2002;43:1104-8.
9. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res, 2001;73:887-96.
10. Medina S, Le Tertre A, Quenel P, Le Moullec Y, Lameloise P, Guzzo JC, Festy B et al. Air pollution and doctor's house calls: results from the ERPURS system for monitoring the effects of air pollution on public health in greater Paris, France, 1991-1995. Environ Res 1997;75:73-84.
11. Yang X, Zhang YP, Chen D, Chen WG, Wang R. Eye irritation caused by formaldehyde as an indoor air pollution: a controlled human exposure experiment. Biomed Environ Sci, 2001;14:229-36.
12. Podlekareva D, Pan Z, Kjaergaard S, Molhave L. Irritation of the human eye mucous membrane caused by airborne pollutants. Int Arch Occup Environ Health, 2002;75:359-64.
13. Jaakkola JJK, Tuomaala P, Seppanen O. Textile wall materials and sick building syndrome. Arch Env Health, 1994;49:175-81.
14. Nel AE, Diaz-Sanchez D, Ng D, Hiura T, Saxon A. Enhancement of allergic inflammation by the interaction between diesel exhaust particles and the immune system. J Allergy Clin Immunol, 1998;102:539-54.
15. Chambellan A, Crestani B, Soler P, Moreau J, Aubier M. Diesel particles and allergy: cellular mechanisms. Allergy Immunol, 2000;32:43-8.
16. Ooi PL, Goh KT, Heng BH, Toh YH. Epidemiological investigations into an outbreak of building-associated illness in Singapore. Asia Pac J Public Health, 1994;7:201-5.
17. Versura P, Profazio V, Cellini M, Torreggiani A, Caramazza R. Eye discomfort and air pollution. Ophtalmologica, 1999;213:103-9.
18. Stiller-Winkler R, Kramer U, Fiedler E, Ewers U, Dolgner R. C3c concentrations in sera of persons living in areas with different levels of air pollution in Northrhine-Westphalia. Environ Res, 1989;49:7-19.
19. Shima M, Adachi M. Effects of environmental tobacco smoke on serum levels of acute phase proteins in schoolchildren. Preventive Med, 1996;25:617-24.
20. Cox FA, Stiller-Winkler R, Hadnagy W, Ranft U, Idel H. Soluble tumor necrosis factor receptor (sTNF RII) in sera of children and traffic-derived particulate air pollution. Zentralbl Hyg Umweltmed, 1999;202:489-500.
21. Kanemitsu H, Nagasawa S, Sagai M, Mori Y. Complement activation by diesel exhaust particles (DEP). Biol Pharm Bull, 1998;21:129-32.
22. Maruo K, Akaike T, Ono T, Okamoto T, Maeda H. Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease. J Allergy Clin Immunol, 1997;100:253-60.
23. Castro FF, Schmitz-Schumann M, Rother U, Kirschfink M. Complement activation by house dust: reduced reactivity of serum complement in patients with bronchial asthma. Int Arch Allergy Appl Immunol, 1991;96:305-10.
24. Barrens L, de la Cuadra Lopez B. Complement activating agents in allergenic extracts. Inflamm Res, 1997;46:455-60.
25. Robbins RA, Nelson KJ, Gossman GL, Koyama S, Rennard SI. Complement activation by cigarette smoke. Am J Physiol, 1991;260:L254-9.
26. Feuillard J, Maillet F, Goldschmidt P, Weiss L, Kazatchkine MD. Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA). Agents Actions, 1991;32:343-6.
27. Etievant M, Leluc B, David B. In vitro inhibition of the classical and the alternative pathways of human complement by N acetyl aspartyl glutamic acid (NAAGA). Agents Actions, 1988;24:137-44.
28. Asghar SS, Pasch MC. Therapeutic inhibition of the complement system. Y2K update. Front Biosci, 2000;5:E63-81.
29. Kirschfink M. Targeting complement in therapy. Immunol Rev, 2001;180:177-89.
30. Harris CL, Williams AS, Linton SM, Morgan BP. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol, 2002;129:198-207.
31. Miyagawa S, Matsunami K, Yoshitatsu M, Mikata S, Matsuda H, Shirakura R. Attempts to prepare suitable complement regulatory molecules for clinical xenotransplantation. J Card Surg, 2001;16:429-38.
32. Durrant LG, Spendlove I. Immunization against tumor cell surface complement-regulatory proteins. Curr Opin Investig Drugs, 2001;2:959-66.